Table 4.
Overall survival – naïve and MAIC (base-case and sensitivity) analyses
| Naïve | Base-case analysis | Sensitivity analysis | |
|---|---|---|---|
| Axitinib (AXIS) vs. cabozantinib (METEOR) | |||
| Axitinib, median (95% CI) OS, months | 15.2 (12.8–18.5) | 21.5 (15.7–27.3) | 15.7 (12.8–21.5) |
| Cabozantinib, median (95% CI) OS, months | 21.5 (17.1–NE) | 21.5 (17.1–NE) | 21.5 (17.1–NE) |
| aHR (95% CI) | – | 1.00 (0.69–1.46) | 1.35 (0.95–1.92) |
| Axitinib (AXIS) vs. everolimus (METEOR) | |||
| Axitinib, median (95% CI) OS, months | 15.2 (12.8–18.5) | 21.7 (13.5–28.3) | 15.5 (12.8–23.1) |
| Everolimus, median (95% CI) OS, months | 16.5 (13.3–19.1) | 16.5 (13.3–19.1) | 16.5 (13.3–19.1) |
| aHR (95% CI) | – | 0.63 (0.42–0.96) | 0.84 (0.59–1.18) |
aHR adjusted hazard ratio, CI confidence interval, MAIC matching-adjusted indirect comparison, MSKCC Memorial Sloan Kettering Cancer Center, NE not estimable, OS overall survival